Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock?
12:55pm, Friday, 24'th Jul 2020
Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:43am, Thursday, 23'rd Jul 2020
BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt. AxoGen completes enrollment in pivotal nerve graft study.
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
11:30am, Tuesday, 21'st Jul 2020
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject.
What Kind Of Shareholders Hold The Majority In InflaRx N.V.'s (NASDAQ:IFRX) Shares?
03:48pm, Thursday, 16'th Jul 2020
The big shareholder groups in InflaRx N.V. (NASDAQ:IFRX) have power over the company. Generally speaking, as a company...
InflaRx Sees Hammer Chart Pattern: Time to Buy?
11:33am, Thursday, 09'th Jul 2020
InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.
Hedge Funds Are Buying InflaRx N.V. (IFRX)
08:05pm, Thursday, 25'th Jun 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today interim results from the first 30 patients trea
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions
12:30pm, Thursday, 11'th Jun 2020
InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
03:10pm, Friday, 29'th May 2020
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
Europe Equities Are Hot on Stimulus Optimism: 5 Picks
12:31pm, Thursday, 28'th May 2020
Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.
InflaRx Reports Q1 2020 Financial & Operating Results
11:30am, Thursday, 21'st May 2020
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1.
Inflarx (NASDAQ:IFRX) versus Synlogic (NASDAQ:SYBX) Head to Head Contrast
05:36am, Saturday, 02'nd May 2020
Inflarx (NASDAQ:IFRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, anal
OSTK, AR among premarket gainers
01:20pm, Thursday, 30'th Apr 2020
LMP Automotive Holdings (NASDAQ:LMPX) +35%.AgEagle Aerial Systems (NYSEMKT:UAVS) +27%.Soligenix (NASDAQ:SNGX) +25% on positive SGX301 data.Secoo Holding (NASDAQ:SECO) +26% on share repurchase progra
Thursday's top analyst upgrades and downgrades included Carvana, Caterpillar, Dollar General, DraftKings, eBay, Facebook, Microsoft, Schlumberger, Spotify and Tesla.
InflaRx up 11% premarket on bullish call at Raymond James
12:33pm, Thursday, 30'th Apr 2020
Citing "imminent data" from its COVID-19 trial and an autoimmune disorder study, Raymond James' Steven Seedhouse has upgraded InflaRx (NASDAQ:IFRX) to Outperform with a $10 (85% upside) price
